Revolution Medicines Inc (Revolution Medicines) is a clinical-stage precision oncology company that discover and developed medicines and therapies for cancer patients. The company product candidate is RMC-4630, a clinical-stage drug candidate that potently and selectively inhibits SHP2, a central node in the RAS signaling pathway. Its other product includes RMC-4630, RMC-5552, SOS1. Revolution Medicines also provide a research and development pipeline comprising RAS(ON) inhibitors that bind directly to RAS variants. The company partners with pharmaceutical companies and healthcare organizations for its drug development activities. Revolution Medicines is headquartered in Redwood City, California, the US
Revolution Medicines Inc premium industry data and analytics
Products and Services
Products |
---|
Medicines and Therapies |
RMC-4630 |
RMC-4630 (SHP2) |
XYZ |
XYZ |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Acquisitions/Mergers/Takeovers | In November, the company acquired EQRx, a biopharmaceutical company. |
2020 | Stock Listings/IPO | In January, the company announced its plans to raise IPO of shares. |
2018 | Acquisitions/Mergers/Takeovers | In October, the company acquired Warp Drive Bio, Inc. |
Competitor Comparison
Key Parameters | Revolution Medicines Inc | Amneal Pharmaceuticals Inc | Surface Oncology Inc | Gritstone Bio Inc | Entasis Therapeutics Holdings Inc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
City | Redwood City | Bridgewater | Cambridge | Emeryville | Waltham |
State/Province | California | New Jersey | Massachusetts | California | Massachusetts |
No. of Employees | 378 | 7,600 | 60 | 231 | 51 |
Entity Type | Public | Public | Private | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Mark A. Goldsmith | Director; President; Chief Executive Officer | Executive Board | 2014 | 61 |
Walter Reiher | Chief Information Officer | Senior Management | - | - |
Shaoling Li | Senior Vice President - CMC and Quality | Senior Management | - | - |
Bojena Bitman | Vice President - Quantitative Sciences | Senior Management | 2019 | - |
Jason Lindow | Vice President - Clinical Operations | Senior Management | - | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward